Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

, ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

10:55
11/30/16
11/30
10:55
11/30/16
10:55

Arrowhead clinical programs halt seen as boost for small-cap peer Arbutus

Shares of Arrowhead Pharmaceuticals (ARWR) are plunging after the company announced that it is stopping the development of all of its drugs currently being tested on humans due to a setback in the drug-delivery technology. Coming only three weeks after the Food and Drug Administration placed its lead asset for hepatitis B virus on clinical hold, the news sparked several rating downgrades by Wall Street analysts. Additionally, Chardan upgraded Arbutus Biopharma (ABUS) to Buy as the firm views the news as a positive for Arrowhead's competitor. CLINICAL PROGRAMS DISCONTINUED: Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv, or EX1, delivery vehicle. Both ARC-520 and ARC-521 were aimed at hepatitis B, while ARC-AAT was intended to fight Alpha-1 antitrypsin deficiency, a rare and hereditary illness that can lead to cirrhosis or cancer. Additionally, the company announced that it is reducing its workforce by approximately 30%, while "maintaining full resourcing necessary to support current and potential future partner-based programs and Arrowhead's burgeoning pipeline." ANALYSTS MOVE TO THE SIDELINES: Piper Jaffray analyst Edward Tenthoff downgraded Arrowhead to Neutral from Overweight after the company discontinued its three clinical RNAi candidates, a decision that was based on the FDA clinical hold on ARC-520 due to deaths in an ongoing non-human primate study of high doses of EX1 delivery vehicle. The analyst noted that this was a "negative surprise," and lowered his price target on the shares to $2 from $10. Tenthoff was not the only analyst moving to the sidelines after the program halt announcement. His peer at Cantor also downgraded Arrowhead to Hold from Buy, citing similar reasons. Analyst Elemer Piros told investors in a note of his own that the company is going to focus on its subcutaneously delivered candidates, which are still in early stages of development and lack visibility. He also lowered his price target on the shares to $1 from $15. Meanwhile, William Blair analyst Katherine Xu also downgraded Arrowhead to Market Perform from Outperform, and lowered her price target on the shares to $2 from $12. While the company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, Xu pointed out that she estimates these programs to be at least one to two years away from entering the clinic. HALT POSITIVE FOR COMPETITOR: Research firm Chardan downgraded Arrowhead to Neutral, while upgrading its competitor Arbutus to Buy. Analyst Madhu Kumar told investors that he now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Moreover, the analyst believes that Arrowhead's discontinuations, which are specific to the dynamic polyconjugate platform, should have minimal read-across to Arbutus and its competing assets such as ARB-1467 and ARB-1740, which do not use the same technology. PRICE ACTION: In morning action, shares of Arrowhead have dropped over 64% to $1.57, while Arbutus' stock has gained over 14% to $3.03 per share.

ARWR

Arrowhead

$4.39

-0.07 (-1.57%)

ABUS

Arbutus Biopharma

$2.65

-0.05 (-1.85%)

  • 30

    Nov

  • 06

    Dec

ARWR Arrowhead
$4.39

-0.07 (-1.57%)

11/30/16
WBLR
11/30/16
DOWNGRADE
WBLR
Market Perform
Arrowhead downgraded to Market Perform from Outperform at William Blair
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded on competitor withdrawal at Chardan
As noted earlier, Chardan upgraded Arbutus (ABUS) to Buy from Neutral. Analyst Gbola Amusa upgraded the stock after Arrowhead (ARWR) announced that it was terminating its intravenously delivered RNAi clinical programs ARC-520, ARC-521, and ARC-AAT. The analyst now expects Arbutus' share of the HBV RNAi to rise to 47.5% from 17.5%. Amusa does not expect Arbutus' treatments to cause the same safety problems as those of Arrowhead. Amusa is upbeat on Arbutus' lead asset, ARB-1467. Target to $4 from $3.
11/30/16
11/30/16
DOWNGRADE
Target $2

Market Perform
Arrowhead downgraded at William Blair after clinical programs discontinued
As previously reported, William Blair analyst Katherine Xu downgraded Arrowhead to Market Perform from Outperform after the company announced that it would discontinue all of its current clinical-stage programs three weeks after the FDA placed lead asset ARC-520 for hepatitis B virus on clinical hold. The company plans to shift focus to its preclinical subcutaneous and extra-hepatic RNAi platforms, though Xu estimates these programs are at least one to two years away from entering the clinic. Xu cut her price target on Arrowhead shares to $2 from $12.
11/30/16
11/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ABUS Arbutus Biopharma
$2.65

-0.05 (-1.85%)

10/14/16
CHDN
10/14/16
UPGRADE
CHDN
Neutral
Arbutus Biopharma upgraded to Neutral from Sell at Chardan
10/14/16
10/14/16
UPGRADE

Neutral
Arbutus Biopharma upgraded to Neutral on valuation at Chardan
As previously reported, Chardan upgraded Arbutus Biopharma to Neutral from Sell. Analyst MadhuKumar upgraded shares citing relative shares underperformance ahead of Q4 and 2017 clinical catalyst in the Phase IIa study of ARB-1467.
11/30/16
CHDN
11/30/16
UPGRADE
CHDN
Buy
Arbutus Biopharma upgraded to Buy from Neutral at Chardan

TODAY'S FREE FLY STORIES

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

, EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

18:07
06/23/17
06/23
18:07
06/23/17
18:07
Hot Stocks
Southern National Bancorp, Eastern Virginia Bankshares complete merger »

Southern National Bancorp…

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$104.84

0.3 (0.29%)

17:56
06/23/17
06/23
17:56
06/23/17
17:56
Hot Stocks
IAC will not pursue plan to create new class of non-voting stock »

IAC's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGL

Engility

$27.37

0.26 (0.96%)

17:50
06/23/17
06/23
17:50
06/23/17
17:50
Hot Stocks
Engility to eliminate position of president, COO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

ADM

Archer Daniels

$41.16

0.13 (0.32%)

17:48
06/23/17
06/23
17:48
06/23/17
17:48
Hot Stocks
ADM Animal Nutrition recalls Rough-N-Ready cattle feed over monensin concerns »

ADM Animal Nutrition, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$35.24

0.03 (0.09%)

17:30
06/23/17
06/23
17:30
06/23/17
17:30
Syndicate
Breaking Syndicate news story on Voya Financial »

Voya Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

, TBK

Triumph Bancorp

17:19
06/23/17
06/23
17:19
06/23/17
17:19
Hot Stocks
Independent Bank to sell nine Colorado branches to TBK Bank »

Independent Bank (IBTX)…

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

TBK

Triumph Bancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

WUBA

58.com

$43.30

0.87 (2.05%)

17:11
06/23/17
06/23
17:11
06/23/17
17:11
Hot Stocks
Breaking Hot Stocks news story on 58.com »

General Atlantic reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

, LGF.B

Lionsgate

$25.38

0.34 (1.36%)

17:10
06/23/17
06/23
17:10
06/23/17
17:10
Hot Stocks
Box Office Battle: 'Transformers' expected to top 'Cars 3,' 'Wonder Woman' »

Viacom (VIA, VIAB)…

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

DIS

Disney

$104.36

0.14 (0.13%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

VIA

Viacom

$39.15

0.1 (0.26%)

SNE

Sony

$38.52

0.11 (0.29%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

TWX

Time Warner

$99.70

0.3 (0.30%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

NVUS

Novus Therapeutics

$6.00

-0.04 (-0.66%)

17:07
06/23/17
06/23
17:07
06/23/17
17:07
Syndicate
Breaking Syndicate news story on Novus Therapeutics  »

Novus Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXG

Interpace Diagnostics

$0.88

0.03 (3.53%)

17:05
06/23/17
06/23
17:05
06/23/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Interpace Diagnostics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$14.95

0.26 (1.77%)

17:02
06/23/17
06/23
17:02
06/23/17
17:02
Hot Stocks
Monmouth Real Estate acquires building in Texas for $50.6M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

ARCW

ARC Group

$3.55

0.15 (4.41%)

17:01
06/23/17
06/23
17:01
06/23/17
17:01
Hot Stocks
ARC Group names Drew Kelley as Interim CEO, effective July 1 »

ARC Group Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAVM

PAVmed

$4.41

-0.08 (-1.78%)

16:55
06/23/17
06/23
16:55
06/23/17
16:55
Syndicate
PAVmed announces effectiveness of Form S-1 resale registration statement »

PAVmed announced that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$36.15

0.9 (2.55%)

16:48
06/23/17
06/23
16:48
06/23/17
16:48
Hot Stocks
MutualFirst Financial senior executives enter 10b5-1 trading plans »

On June 23, David Heeter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.10

0.25 (0.78%)

16:46
06/23/17
06/23
16:46
06/23/17
16:46
Hot Stocks
Cisco CEO Charles Robbins enters 10b5-1 trading plan »

On June 21, Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

  • 16

    Aug

SITO

SITO Mobile

$3.66

0.02 (0.55%)

16:43
06/23/17
06/23
16:43
06/23/17
16:43
Hot Stocks
SITO Mobile chairman Paul Pressler resigns »

Effective as of June 23,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$517.33

-9.2 (-1.75%)

, CELG

Celgene

$134.31

0.63 (0.47%)

16:41
06/23/17
06/23
16:41
06/23/17
16:41
General news
S&P sees mild weekly gain, Nasdaq outperforms as biotech shines »

The S&P finished the…

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

GILD

Gilead

$70.54

0.06 (0.09%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

ABBV

AbbVie

$72.64

-0.54 (-0.74%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BA

Boeing

$202.23

2.79 (1.40%)

ORCL

Oracle

$50.95

0.65 (1.29%)

EQT

EQT Corporation

$56.19

4.16 (8.00%)

RICE

Rice Energy

$25.65

1.62 (6.74%)

SYK

Stryker

$141.12

-0.1 (-0.07%)

NVDQ

Novadaq

$11.78

-0.02 (-0.17%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

LH

LabCorp

$151.62

1.28 (0.85%)

ICLR

ICON plc

$96.37

-0.26 (-0.27%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AMD

AMD

$14.15

-0.23 (-1.60%)

LZB

La-Z-Boy

$32.30

0.7 (2.22%)

RHT

Red Hat

$99.42

0.54 (0.55%)

AAL

American Airlines

$48.63

-0.34 (-0.69%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

THC

Tenet

$18.52

-0.38 (-2.01%)

SCS

Steelcase

$13.65

-0.45 (-3.19%)

ACN

Accenture

$122.74

0.66 (0.54%)

BBBY

Bed Bath & Beyond

$29.65

-4.09 (-12.12%)

BBRY

BlackBerry

$9.71

-1.35 (-12.21%)

BAC

Bank of America

$22.82

-0.11 (-0.48%)

C

Citi

$63.41

-0.21 (-0.33%)

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

JPM

JPMorgan

$86.86

-0.16 (-0.18%)

MS

Morgan Stanley

$43.69

-0.92 (-2.06%)

WFC

Wells Fargo

$52.45

-0.04 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 07

    Jul

  • 13

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

  • 29

    Aug

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 23

    Oct

  • 14

    Nov

  • 15

    Jan

  • 03

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:39
06/23/17
06/23
16:39
06/23/17
16:39
General news
Moody's raises Greece rating to Caa2 from Caa3, outlook to positive from stable »

Moody's has upgraded…

CFCO

CF Corporation

$11.42

-0.04 (-0.35%)

16:38
06/23/17
06/23
16:38
06/23/17
16:38
Hot Stocks
Breaking Hot Stocks news story on CF Corporation »

Mason Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.